|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
multiple interactions |
EXP |
Silybin affects the localization of and affects the activity of ABCB11 protein |
CTD |
PMID:15763547 |
|
NCBI chr 3:55,480,024...55,587,946
Ensembl chr 3:55,480,024...55,587,946
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
multiple interactions increases phosphorylation |
ISO |
Silybin inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in decreased phosphorylation of ACACA protein] Silybin results in increased phosphorylation of ACACA protein |
CTD |
PMID:25294820 PMID:25559859 |
|
NCBI chr10:71,519,392...71,719,910
Ensembl chr10:71,536,533...71,719,910
|
|
G |
Acly |
ATP citrate lyase |
decreases phosphorylation |
ISO |
Silybin results in decreased phosphorylation of ACLY protein |
CTD |
PMID:25294820 |
|
NCBI chr10:88,392,248...88,442,845
Ensembl chr10:88,392,248...88,442,845
|
|
G |
Adipor2 |
adiponectin receptor 2 |
increases expression |
EXP |
silymarin (silibinin) increases expression of adipor2 mRNA and protein in epididymal white adipose tissue of alcohol fed rats |
RGD |
PMID:26115886 |
RGD:25330099 |
NCBI chr 4:151,412,135...151,480,108
Ensembl chr 4:151,414,684...151,428,894
|
|
G |
Agpat3 |
1-acylglycerol-3-phosphate O-acyltransferase 3 |
multiple interactions |
EXP |
Silybin inhibits the reaction [[Zidovudine co-treated with Isoniazid] results in increased expression of AGPAT3 mRNA] |
CTD |
PMID:28619387 |
|
NCBI chr20:11,060,584...11,144,806
Ensembl chr20:11,114,164...11,144,806
|
|
G |
Akr1c3 |
aldo-keto reductase family 1, member C3 |
decreases activity |
ISO |
Silybin results in decreased activity of AKR1C3 protein |
CTD |
PMID:19007764 |
|
NCBI chr17:69,761,126...69,778,021
Ensembl chr17:69,761,118...69,778,021
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
Silybin inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:25559859 |
|
NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
|
|
G |
Amacr |
alpha-methylacyl-CoA racemase |
decreases expression |
ISO |
Silybin results in decreased expression of AMACR protein |
CTD |
PMID:25294820 |
|
NCBI chr 2:60,949,276...60,961,342
Ensembl chr 2:60,949,256...60,961,326
|
|
G |
Apoa5 |
apolipoprotein A5 |
multiple interactions |
EXP |
Silybin inhibits the reaction [[Zidovudine co-treated with Isoniazid] results in decreased expression of APOA5 mRNA] |
CTD |
PMID:28619387 |
|
NCBI chr 8:50,559,079...50,561,720
Ensembl chr 8:50,559,126...50,561,736
|
|
G |
Asl |
argininosuccinate lyase |
multiple interactions |
EXP |
Silybin inhibits the reaction [[Isoniazid co-treated with Zidovudine] results in increased activity of ASL protein] |
CTD |
PMID:28619387 |
|
NCBI chr12:30,160,922...30,178,348
Ensembl chr12:30,165,694...30,178,341
|
|
G |
Atm |
ATM serine/threonine kinase |
multiple interactions |
ISO |
Silybin results in increased phosphorylation of and results in increased activity of ATM protein |
CTD |
PMID:16777994 |
|
NCBI chr 8:58,015,938...58,119,973
Ensembl chr 8:58,015,940...58,120,045
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
Silybin inhibits the reaction [Mitomycin affects the localization of BAX protein] |
CTD |
PMID:19834285 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression multiple interactions |
ISO |
Silybin results in decreased expression of BCL2 mRNA [Silybin co-treated with Arsenic Trioxide] results in decreased expression of BCL2 mRNA; Silybin inhibits the reaction [Mitomycin affects the expression of BCL2] |
CTD |
PMID:19834285 PMID:21969006 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Bid |
BH3 interacting domain death agonist |
multiple interactions increases cleavage affects localization |
ISO |
benzoylcarbonyl-valyl-aspartyl-valyl-alanyl-aspartyl-fluoromethyl ketone inhibits the reaction [Silybin results in increased cleavage of BID protein]; Caffeine inhibits the reaction [Silybin results in increased cleavage of BID protein]; pifithrin inhibits the reaction [Silybin results in increased cleavage of BID protein] Silybin affects the localization of BID protein modified form |
CTD |
PMID:16777994 |
|
NCBI chr 4:153,439,812...153,465,247
Ensembl chr 4:153,442,218...153,465,203
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
multiple interactions |
ISO |
[Silybin co-treated with Arsenic Trioxide] results in decreased expression of BIRC5 mRNA |
CTD |
PMID:21969006 |
|
NCBI chr10:106,856,097...106,864,419
Ensembl chr10:106,856,097...106,864,413
|
|
G |
Ca9 |
carbonic anhydrase 9 |
decreases expression multiple interactions |
ISO |
Silybin results in decreased expression of CA9 mRNA Arsenic Trioxide promotes the reaction [Silybin results in decreased expression of CA9 mRNA] |
CTD |
PMID:21969006 |
|
NCBI chr 5:59,008,277...59,015,535
Ensembl chr 5:59,008,933...59,015,528
|
|
G |
Casp2 |
caspase 2 |
multiple interactions |
ISO |
benzoylcarbonyl-valyl-aspartyl-valyl-alanyl-aspartyl-fluoromethyl ketone inhibits the reaction [Silybin results in increased cleavage of and results in increased activity of CASP2 protein]; Caffeine inhibits the reaction [Silybin results in increased cleavage of and results in increased activity of CASP2 protein]; pifithrin inhibits the reaction [Silybin results in increased cleavage of and results in increased activity of CASP2 protein]; Silybin results in increased cleavage of and results in increased activity of CASP2 protein |
CTD |
PMID:16777994 |
|
NCBI chr 4:71,652,358...71,670,228
Ensembl chr 4:71,652,354...71,670,239
|
|
G |
Casp3 |
caspase 3 |
increases expression multiple interactions increases activity |
ISO |
Silybin results in increased expression of CASP3 mRNA Arsenic Trioxide promotes the reaction [Silybin results in increased activity of CASP3 protein]; benzoylcarbonyl-valyl-aspartyl-valyl-alanyl-aspartyl-fluoromethyl ketone inhibits the reaction [Silybin results in increased cleavage of and results in increased activity of CASP3 protein]; Caffeine inhibits the reaction [Silybin results in increased cleavage of and results in increased activity of CASP3 protein]; pifithrin inhibits the reaction [Silybin results in increased cleavage of and results in increased activity of CASP3 protein]; Silybin promotes the reaction [Arsenic Trioxide results in increased expression of CASP3 mRNA]; Silybin results in increased cleavage of and results in increased activity of CASP3 protein |
CTD |
PMID:16777994 PMID:21969006 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO |
benzoylcarbonyl-valyl-aspartyl-valyl-alanyl-aspartyl-fluoromethyl ketone inhibits the reaction [Silybin results in increased cleavage of and results in increased activity of CASP8 protein]; pifithrin inhibits the reaction [Silybin results in increased cleavage of and results in increased activity of CASP8 protein]; Silybin results in increased cleavage of and results in increased activity of CASP8 protein |
CTD |
PMID:16777994 |
|
NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
ISO |
benzoylcarbonyl-valyl-aspartyl-valyl-alanyl-aspartyl-fluoromethyl ketone inhibits the reaction [Silybin results in increased cleavage of and results in increased activity of CASP9 protein]; Caffeine inhibits the reaction [Silybin results in increased cleavage of and results in increased activity of CASP9 protein]; pifithrin inhibits the reaction [Silybin results in increased cleavage of and results in increased activity of CASP9 protein]; Silybin results in increased cleavage of and results in increased activity of CASP9 protein |
CTD |
PMID:16777994 |
|
NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
Silybin inhibits the reaction [Arsenic results in decreased activity of CAT protein]; Silybin inhibits the reaction [sodium arsenite results in decreased expression of CAT] |
CTD |
PMID:22229868 PMID:23070905 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Ccna2 |
cyclin A2 |
multiple interactions |
ISO |
Silybin inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of CCNA2 protein] |
CTD |
PMID:25559859 |
|
NCBI chr 2:123,274,727...123,282,266
Ensembl chr 2:123,275,881...123,282,214
|
|
G |
Ccnb1 |
cyclin B1 |
multiple interactions |
ISO |
Silybin inhibits the reaction [Arsenic results in increased expression of CCNB1] |
CTD |
PMID:25868784 |
|
NCBI chr 2:30,782,133...30,791,106
Ensembl chr 2:30,783,915...30,791,221
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions decreases expression |
ISO |
Silybin inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of CCND1 protein] Silybin results in decreased expression of CCND1 protein [Silybin co-treated with Arsenic] results in decreased expression of CCND1 protein |
CTD |
PMID:16788158 PMID:25559859 PMID:25868784 |
|
NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
|
|
G |
Ccnd3 |
cyclin D3 |
multiple interactions |
ISO |
[Silybin co-treated with Arsenic] results in decreased expression of CCND3 protein |
CTD |
PMID:25868784 |
|
NCBI chr 9:15,404,816...15,410,905
Ensembl chr 9:15,404,822...15,410,943
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
multiple interactions |
ISO |
Silybin inhibits the reaction [Arsenic results in increased expression of CDK1 protein] |
CTD |
PMID:25868784 |
|
NCBI chr20:20,576,341...20,591,510
Ensembl chr20:20,576,377...20,591,549
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
multiple interactions |
ISO |
[Silybin co-treated with Arsenic] results in decreased expression of CDK2 protein |
CTD |
PMID:25868784 |
|
NCBI chr 7:3,124,953...3,132,533
Ensembl chr 7:3,124,954...3,132,457
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
multiple interactions |
ISO |
[Silybin co-treated with Arsenic] results in decreased expression of CDK4 protein |
CTD |
PMID:25868784 |
|
NCBI chr 7:70,345,971...70,352,689
Ensembl chr 7:70,349,863...70,352,418
|
|
G |
Cdk6 |
cyclin-dependent kinase 6 |
multiple interactions |
ISO |
[Silybin co-treated with Arsenic] results in decreased expression of CDK6 protein |
CTD |
PMID:25868784 |
|
NCBI chr 4:27,781,728...27,969,653
Ensembl chr 4:27,785,647...27,966,398
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions increases cleavage |
ISO |
[Silybin co-treated with Arsenic] results in increased expression of CDKN1A protein; benzoylcarbonyl-valyl-aspartyl-valyl-alanyl-aspartyl-fluoromethyl ketone inhibits the reaction [Silybin results in increased cleavage of CDKN1A protein] |
CTD |
PMID:16777994 PMID:25868784 |
|
NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
multiple interactions |
ISO |
Silybin inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in decreased expression of CDKN1B protein] [Silybin co-treated with Arsenic] results in increased expression of CDKN1B protein |
CTD |
PMID:25559859 PMID:25868784 |
|
NCBI chr 4:168,689,043...168,694,159
Ensembl chr 4:168,689,163...168,693,964
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
multiple interactions |
ISO |
Silybin inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of CEBPA protein] |
CTD |
PMID:25559859 |
|
NCBI chr 1:91,363,492...91,366,164
Ensembl chr 1:91,363,492...91,366,164
|
|
G |
Chek2 |
checkpoint kinase 2 |
increases phosphorylation multiple interactions |
ISO |
Silybin results in increased phosphorylation of CHEK2 protein Caffeine inhibits the reaction [Silybin results in increased phosphorylation of CHEK2 protein] |
CTD |
PMID:16777994 |
|
NCBI chr12:51,845,574...51,878,098
Ensembl chr12:51,845,796...51,877,624
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
multiple interactions |
EXP |
[Silybin co-treated with Phosphatidylcholines co-treated with Vitamin E] inhibits the reaction [Dimethylnitrosamine results in increased expression of COL1A1 mRNA] |
CTD |
PMID:16169303 |
|
NCBI chr10:82,745,801...82,762,790
Ensembl chr10:82,745,801...82,762,789
|
|
G |
Ctsb |
cathepsin B |
multiple interactions |
ISO |
[Arsenic Trioxide co-treated with Silybin] results in decreased expression of CTSB mRNA |
CTD |
PMID:21969006 |
|
NCBI chr15:46,316,741...46,337,613
Ensembl chr15:46,316,741...46,337,612
|
|
G |
Cyb5a |
cytochrome b5 type A |
multiple interactions |
EXP |
Silybin inhibits the reaction [[Zidovudine co-treated with Isoniazid] results in decreased expression of CYB5A mRNA] |
CTD |
PMID:28619387 |
|
NCBI chr18:81,694,818...81,726,821
Ensembl chr18:81,694,808...81,726,821
|
|
G |
Cybb |
cytochrome b-245 beta chain |
multiple interactions |
EXP |
Silybin inhibits the reaction [sodium arsenite results in increased expression of CYBB] |
CTD |
PMID:24062023 |
|
NCBI chr X:14,578,330...14,610,049
Ensembl chr X:14,578,264...14,612,547
|
|
G |
Cyp2c79 |
cytochrome P450, family 2, subfamily c, polypeptide 79 |
decreases activity |
ISO |
Silybin results in decreased activity of CYP2C8 protein |
CTD |
PMID:28457856 |
|
NCBI chr 1:147,236,480...147,307,988
|
|
G |
Cyp3a62 |
cytochrome P450, family 3, subfamily a, polypeptide 62 |
decreases activity multiple interactions |
ISO |
Silybin results in decreased activity of CYP3A4 protein Silybin inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Testosterone] |
CTD |
PMID:15155549 |
|
NCBI chr12:18,679,809...18,709,397
Ensembl chr12:18,678,594...18,709,397
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions |
ISO |
DDIT3 affects the reaction [Silybin results in increased expression of TNFRSF10B] |
CTD |
PMID:19939880 |
|
NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
|
|
G |
Dlk1 |
delta like non-canonical Notch ligand 1 |
multiple interactions |
ISO |
Silybin inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in decreased expression of DLK1 mRNA] |
CTD |
PMID:25559859 |
|
NCBI chr 6:133,576,513...133,583,751
Ensembl chr 6:133,552,821...133,583,751
|
|
G |
Egr1 |
early growth response 1 |
increases expression multiple interactions |
ISO |
Silybin results in increased expression of EGR1 protein EGR1 mutant form inhibits the reaction [Silybin results in increased expression of GDF15 protein] |
CTD |
PMID:24440808 |
|
NCBI chr18:27,657,903...27,660,101
Ensembl chr18:27,657,628...27,661,429
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions |
EXP ISO |
Silybin results in increased activity of [ESR1 protein binds to ESR2 protein] |
CTD |
PMID:16076518 |
|
NCBI chr 1:41,192,029...41,594,799
Ensembl chr 1:41,192,824...41,594,796
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions |
ISO EXP |
Silybin results in increased activity of [ESR1 protein binds to ESR2 protein] |
CTD |
PMID:16076518 |
|
NCBI chr 6:99,163,953...99,214,711
Ensembl chr 6:99,164,357...99,214,251
|
|
G |
Fabp4 |
fatty acid binding protein 4 |
multiple interactions |
ISO |
Silybin inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of FABP4 protein] |
CTD |
PMID:25559859 |
|
NCBI chr 2:93,792,666...93,797,267
Ensembl chr 2:93,792,601...93,797,305
|
|
G |
Fasn |
fatty acid synthase |
multiple interactions decreases expression |
ISO |
Silybin inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of FASN protein] Silybin results in decreased expression of FASN protein |
CTD |
PMID:25294820 PMID:25559859 |
|
NCBI chr10:109,987,735...110,005,901
Ensembl chr10:109,987,735...110,005,901
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
multiple interactions |
ISO |
Silybin inhibits the reaction [Urethane results in increased secretion of FGF2 protein] |
CTD |
PMID:16788158 |
|
NCBI chr 2:124,081,072...124,134,133
Ensembl chr 2:124,081,072...124,134,681
|
|
G |
G6pd |
glucose-6-phosphate dehydrogenase |
multiple interactions |
EXP |
Silybin inhibits the reaction [Arsenic results in decreased activity of G6PD protein] |
CTD |
PMID:22229868 |
|
NCBI chr X:156,274,800...156,293,935
Ensembl chr X:156,274,800...156,293,926
|
|
G |
Gdf15 |
growth differentiation factor 15 |
increases expression multiple interactions |
ISO |
Silybin results in increased expression of GDF15 mRNA; Silybin results in increased expression of GDF15 protein EGR1 mutant form inhibits the reaction [Silybin results in increased expression of GDF15 protein]; GDF15 mutant form inhibits the reaction [Silybin results in increased cleavage of PARP1 protein]; pyrazolanthrone promotes the reaction [Silybin results in increased expression of GDF15 protein]; SB 203580 inhibits the reaction [Silybin results in increased expression of GDF15 protein] |
CTD |
PMID:24440808 |
|
NCBI chr16:20,555,395...20,557,978
Ensembl chr16:20,555,395...20,557,978
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
EXP |
Silybin inhibits the reaction [Isoniazid promotes the reaction [Zidovudine results in increased activity of GPT protein]] |
CTD |
PMID:28619387 |
|
NCBI chr 7:117,759,083...117,761,932
Ensembl chr 7:117,759,083...117,761,931
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
EXP |
Silybin inhibits the reaction [Arsenic results in decreased activity of GSR protein] |
CTD |
PMID:22229868 |
|
NCBI chr16:62,197,617...62,239,987
Ensembl chr16:62,197,617...62,241,361
|
|
G |
H2ax |
H2A.X variant histone |
multiple interactions increases phosphorylation |
ISO |
Caffeine inhibits the reaction [Silybin results in increased phosphorylation of H2AX protein] |
CTD |
PMID:16777994 |
|
NCBI chr 8:48,665,652...48,666,981
Ensembl chr 8:48,665,652...48,666,981
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
decreases expression |
ISO |
Silybin results in decreased expression of HMGCR protein |
CTD |
PMID:25294820 |
|
NCBI chr 2:27,480,224...27,500,654
Ensembl chr 2:27,480,226...27,500,654
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
EXP |
Silybin inhibits the reaction [sodium arsenite results in decreased expression of HMOX1] |
CTD |
PMID:24062023 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Keap1 |
Kelch-like ECH-associated protein 1 |
multiple interactions |
EXP |
Silybin inhibits the reaction [sodium arsenite results in increased expression of KEAP1] |
CTD |
PMID:24062023 |
|
NCBI chr 8:22,250,518...22,259,868
Ensembl chr 8:22,250,518...22,259,779
|
|
G |
Klf2 |
Kruppel-like factor 2 |
multiple interactions |
ISO |
Silybin inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in decreased expression of KLF2 mRNA] |
CTD |
PMID:25559859 |
|
NCBI chr16:19,223,087...19,225,037
Ensembl chr16:19,223,087...19,225,037
|
|
G |
Klf4 |
Kruppel like factor 4 |
multiple interactions |
ISO |
Silybin inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of KLF4 mRNA] |
CTD |
PMID:25559859 |
|
NCBI chr 5:72,283,311...72,287,669
Ensembl chr 5:72,283,313...72,287,669
|
|
G |
Klf5 |
Kruppel-like factor 5 |
multiple interactions |
ISO |
Silybin inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of KLF5 mRNA] |
CTD |
PMID:25559859 |
|
NCBI chr15:83,703,796...83,722,921
Ensembl chr15:83,703,791...83,722,921
|
|
G |
Lpin1 |
lipin 1 |
multiple interactions |
ISO |
Silybin inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of LPIN1 protein] |
CTD |
PMID:25559859 |
|
NCBI chr 6:41,796,214...41,905,149
Ensembl chr 6:41,799,749...41,870,046
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
Silybin inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:25559859 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
Silybin inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:25559859 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
increases phosphorylation multiple interactions |
ISO |
Silybin results in increased phosphorylation of MAPK8 protein pifithrin inhibits the reaction [Silybin results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [Silybin results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:16777994 |
|
NCBI chr16:9,620,854...9,709,342
Ensembl chr16:9,625,177...9,709,347
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
multiple interactions increases phosphorylation |
ISO |
pifithrin inhibits the reaction [Silybin results in increased phosphorylation of MAPK9 protein]; pyrazolanthrone inhibits the reaction [Silybin results in increased phosphorylation of MAPK9 protein] |
CTD |
PMID:16777994 |
|
NCBI chr10:35,333,859...35,374,364
Ensembl chr10:35,333,859...35,374,355
|
|
G |
Mgmt |
O-6-methylguanine-DNA methyltransferase |
multiple interactions |
ISO |
Silybin results in increased expression of and results in increased activity of MGMT protein |
CTD |
PMID:16950796 |
|
NCBI chr 1:209,237,255...209,464,189
Ensembl chr 1:209,237,233...209,464,190
|
|
G |
Mmp14 |
matrix metallopeptidase 14 |
multiple interactions |
ISO |
[Arsenic Trioxide co-treated with Silybin] results in decreased expression of MMP14 mRNA; Arsenic Trioxide inhibits the reaction [Silybin results in increased expression of MMP14 mRNA] |
CTD |
PMID:21969006 |
|
NCBI chr15:33,074,441...33,083,666
Ensembl chr15:33,074,441...33,083,655
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
increases expression multiple interactions |
ISO EXP |
Silybin results in increased expression of MMP2 mRNA [Silybin co-treated with Phosphatidylcholines co-treated with Vitamin E] inhibits the reaction [Dimethylnitrosamine results in increased expression of MMP2 mRNA] [Arsenic Trioxide co-treated with Silybin] results in decreased activity of MMP2 protein; [Arsenic Trioxide co-treated with Silybin] results in decreased expression of MMP2 mRNA; [Silybin co-treated with Arsenic] results in decreased expression of MMP2; Silybin promotes the reaction [Arsenic Trioxide results in decreased expression of MMP2 mRNA] |
CTD |
PMID:16169303 PMID:21969006 PMID:25868784 |
|
NCBI chr19:15,542,771...15,570,589
Ensembl chr19:15,542,765...15,570,611
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
decreases expression multiple interactions decreases activity |
ISO |
Silybin results in decreased expression of MMP9 mRNA [Arsenic Trioxide co-treated with Silybin] results in decreased expression of MMP9 mRNA; [Silybin co-treated with Arsenic Trioxide] results in decreased activity of MMP9 protein Silybin results in decreased activity of MMP9 protein |
CTD |
PMID:21969006 |
|
NCBI chr 3:161,413,410...161,421,473
Ensembl chr 3:161,413,298...161,421,520
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
decreases expression |
ISO |
Silybin results in decreased expression of MYC protein |
CTD |
PMID:27746612 |
|
NCBI chr 7:102,586,313...102,591,240
Ensembl chr 7:102,586,313...102,591,240
|
|
G |
Nat2 |
N-acetyltransferase 2 |
multiple interactions |
EXP |
Silybin inhibits the reaction [[Zidovudine co-treated with Isoniazid] results in decreased expression of NAT2 mRNA] |
CTD |
PMID:28619387 |
|
NCBI chr16:23,960,709...23,991,570
Ensembl chr16:23,961,067...23,991,570
|
|
G |
Nfe2l2 |
nuclear factor, erythroid 2-like 2 |
multiple interactions |
EXP |
Silybin inhibits the reaction [sodium arsenite results in decreased expression of NFE2L2] |
CTD |
PMID:24062023 |
|
NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions decreases expression |
EXP ISO |
Silybin inhibits the reaction [sodium arsenite results in increased expression of NOS2] Silybin results in decreased expression of NOS2 protein |
CTD |
PMID:16788158 PMID:23070905 |
|
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
|
|
G |
Nox4 |
NADPH oxidase 4 |
multiple interactions |
EXP |
Silybin inhibits the reaction [sodium arsenite results in increased expression of NOX4] |
CTD |
PMID:24062023 |
|
NCBI chr 1:150,796,359...150,976,186
Ensembl chr 1:150,797,084...150,976,194
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
decreases expression multiple interactions |
IEP ISO |
Silymarin decreases Nqo1 mRNA in liver Silybin inhibits the reaction [cyfluthrin results in decreased activity of NQO1 protein] |
CTD |
PMID:31330490, PMID:31432116 |
RGD:25823187 |
NCBI chr19:38,422,210...38,437,103
Ensembl chr19:38,422,164...38,437,180
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
increases expression |
EXP |
silymarin increases Nr1h4 mRNA expression in rat kidney and liver |
RGD |
PMID:30308196 |
RGD:15042865 |
NCBI chr 7:30,003,429...30,162,095
Ensembl chr 7:30,003,429...30,162,056
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
increases expression |
ISO |
Silybin results in increased expression of NR1I2 mRNA |
CTD |
PMID:29933105 |
|
NCBI chr11:65,022,100...65,058,546
Ensembl chr11:65,022,100...65,058,545
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage multiple interactions |
ISO |
Silybin results in increased cleavage of PARP1 protein benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [Silybin results in increased cleavage of PARP1 protein]; GDF15 mutant form inhibits the reaction [Silybin results in increased cleavage of PARP1 protein]; pifithrin inhibits the reaction [Silybin results in increased cleavage of PARP1 protein]; Silybin results in increased cleavage of and results in increased activity of PARP1 protein |
CTD |
PMID:16777994 PMID:24440808 |
|
NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
|
|
G |
Pcna |
proliferating cell nuclear antigen |
decreases expression |
ISO |
Silybin results in decreased expression of PCNA protein |
CTD |
PMID:16788158 |
|
NCBI chr 3:124,880,698...124,884,570
Ensembl chr 3:124,880,698...124,884,570
|
|
G |
Pecam1 |
platelet and endothelial cell adhesion molecule 1 |
decreases expression |
ISO |
Silybin results in decreased expression of PECAM1 protein |
CTD |
PMID:16788158 |
|
NCBI chr10:94,850,971...94,913,202
|
|
G |
Plau |
plasminogen activator, urokinase |
multiple interactions decreases expression |
ISO |
[Silybin co-treated with Arsenic Trioxide] results in decreased expression of PLAU mRNA; Arsenic Trioxide promotes the reaction [Silybin results in decreased expression of PLAU mRNA]; Silybin promotes the reaction [Arsenic Trioxide results in decreased expression of PLAU mRNA] |
CTD |
PMID:21969006 |
|
NCBI chr15:3,644,296...3,650,765
Ensembl chr15:3,644,769...3,650,819
|
|
G |
Por |
cytochrome p450 oxidoreductase |
multiple interactions |
EXP |
Silybin inhibits the reaction [[Zidovudine co-treated with Isoniazid] results in decreased expression of POR mRNA] |
CTD |
PMID:28619387 |
|
NCBI chr12:23,998,411...24,017,063
Ensembl chr12:23,998,411...24,046,814
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions increases expression |
ISO |
Silybin inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of PPARG protein] Silybin results in increased expression of PPARG protein |
CTD |
PMID:25559859 PMID:27746612 |
|
NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
decreases expression |
ISO |
Silybin results in decreased expression of PTGS2 protein |
CTD |
PMID:16788158 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
multiple interactions |
ISO |
Silybin inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased phosphorylation of RB1 protein] |
CTD |
PMID:25559859 |
|
NCBI chr15:55,081,582...55,209,060
Ensembl chr15:55,083,140...55,209,342
|
|
G |
Slc16a1 |
solute carrier family 16 member 1 |
multiple interactions |
ISO |
Silybin inhibits the reaction [SLC16A1 protein results in increased uptake of Benzoic Acid] |
CTD |
PMID:17976262 |
|
NCBI chr 2:207,108,552...207,129,352
Ensembl chr 2:207,108,552...207,128,554
|
|
G |
Slc2a4 |
solute carrier family 2 member 4 |
multiple interactions |
ISO |
Silybin inhibits the reaction [INS1 protein affects the localization of SLC2A4 protein] |
CTD |
PMID:18591783 |
|
NCBI chr10:56,552,921...56,558,562
Ensembl chr10:56,552,983...56,558,487
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions decreases response to substance |
ISO |
fatostatin promotes the reaction [Silybin results in decreased cleavage of SREBF1 protein]; Silybin results in decreased cleavage of and results in increased phosphorylation of SREBF1 protein SREBF1 protein results in decreased susceptibility to Silybin |
CTD |
PMID:25294820 |
|
NCBI chr10:46,570,996...46,593,021
Ensembl chr10:46,570,996...46,593,009
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
EXP |
[Silybin co-treated with Phosphatidylcholines co-treated with Vitamin E] inhibits the reaction [Dimethylnitrosamine results in increased expression of TGFB1 mRNA] |
CTD |
PMID:16169303 |
|
NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
multiple interactions |
EXP |
[Silybin co-treated with Phosphatidylcholines co-treated with Vitamin E] inhibits the reaction [Dimethylnitrosamine results in increased expression of TIMP1 mRNA] |
CTD |
PMID:16169303 |
|
NCBI chr X:1,364,771...1,369,451
Ensembl chr X:1,364,786...1,369,384
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP |
Silybin inhibits the reaction [[Isoniazid co-treated with Zidovudine] results in increased expression of TNF protein] |
CTD |
PMID:28619387 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000 Ensembl chr20:5,189,390...5,192,000
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions affects localization increases phosphorylation increases expression |
ISO |
Caffeine inhibits the reaction [Silybin results in increased phosphorylation of TP53 protein]; pifithrin inhibits the reaction [Silybin results in increased phosphorylation of TP53 protein]; Silybin inhibits the reaction [Mitomycin results in increased expression of TP53] Silybin affects the localization of TP53 protein Silybin results in increased expression of TP53 protein |
CTD |
PMID:16777994 PMID:19834285 |
|
NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
decreases activity multiple interactions |
EXP ISO |
Silybin metabolite results in decreased activity of UGT1A1 protein Silybin inhibits the reaction [UGT1A1 protein results in increased glucuronidation of 7-hydroxy-4-trifluoromethylcoumarin] |
CTD |
PMID:15155549 PMID:15921999 |
|
NCBI chr 9:95,295,701...95,302,822
Ensembl chr 9:95,161,157...95,302,822
|
|
G |
Ugt1a6 |
UDP glucuronosyltransferase family 1 member A6 |
multiple interactions decreases activity |
ISO EXP |
Silybin inhibits the reaction [UGT1A6 protein results in increased glucuronidation of 7-hydroxy-4-trifluoromethylcoumarin] Silybin metabolite results in decreased activity of UGT1A6 protein |
CTD |
PMID:15155549 PMID:15921999 |
|
NCBI chr 9:95,241,609...95,302,822
Ensembl chr 9:95,161,157...95,302,822
|
|
G |
Ugt1a9 |
UDP glucuronosyltransferase family 1 member A9 |
multiple interactions |
ISO |
Silybin inhibits the reaction [UGT1A9 protein results in increased glucuronidation of 7-hydroxy-4-trifluoromethylcoumarin] |
CTD |
PMID:15155549 |
|
NCBI chr 9:95,161,157...95,302,822
Ensembl chr 9:95,161,157...95,302,822
|
|
G |
Ugt2b7 |
UDP glucuronosyltransferase family 2 member B7 |
multiple interactions |
ISO |
Silybin inhibits the reaction [UGT2B7 protein results in increased glucuronidation of 7-hydroxy-4-trifluoromethylcoumarin] |
CTD |
PMID:15155549 |
|
NCBI chr14:22,597,103...22,619,968
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions decreases expression |
ISO |
Silybin promotes the reaction [Lipids deficiency inhibits the reaction [Oxygen deficiency results in increased expression of VEGFA protein]]; Silybin promotes the reaction [Lipids deficiency results in decreased expression of VEGFA protein] Silybin results in decreased expression of VEGFA protein Silybin inhibits the reaction [Urethane results in increased secretion of VEGFA protein] |
CTD |
PMID:16788158 PMID:26087400 |
|
NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
|
|
G |
Vim |
vimentin |
multiple interactions |
ISO |
[Silybin co-treated with Arsenic] results in decreased expression of VIM |
CTD |
PMID:25868784 |
|
NCBI chr17:80,882,715...80,891,200
Ensembl chr17:80,882,666...80,891,212
|
|
|
G |
Car1 |
carbonic anhydrase 1 |
decreases activity |
ISO |
silychristin results in decreased activity of CA1 protein |
CTD |
PMID:28445001 |
|
NCBI chr 2:88,185,204...88,227,486
Ensembl chr 2:88,217,188...88,227,479
|
|
G |
Car2 |
carbonic anhydrase 2 |
decreases activity |
ISO |
silychristin results in decreased activity of CA2 protein |
CTD |
PMID:28445001 |
|
NCBI chr 2:88,097,740...88,112,868
Ensembl chr 2:88,097,720...88,113,029
|
|